Acquired and Inherited Thrombophilia Disorders in Pregnancy

Obstetrics and Gynecology Clinics of North America

Volumn 38, Issue 2, 2011, Pages 271-295

  Pierangeli, Silvia S ^a   Leader, Benjamin ^b   Barilaro, Giuseppe ^a   Willis, Rohan ^a   Branch, D Ware ^c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Clinical Research Division and Reprosource Inc   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Pregnancy loss; Thrombosis in pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; CHEMOKINE; HEPARIN; IMMUNOGLOBULIN A; LIPOCORTIN 5; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C5; PHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL; PROTHROMBIN ANTIBODY; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; FETUS DEATH; HEREDITY; HUMAN; IMMUNE INJURY; MATERNAL MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PLACENTA DISORDER; PLACENTAL TRANSFER; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DISORDER; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW; THROMBOPHILIA; THROMBOSIS;

FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; THROMBOPHILIA;

EID: 79955966231     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2011.02.016     Document Type: Review

References (110)

1. Harris E.N. Syndrome of the black swan. Br J Rheumatol 1987, 26:324-326.
2. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
3. Branch D.W., Gibson M., Silver R.M. Clinical practice. Recurrent miscarriage. N Engl J Med 2010, 363:1740-1747.
4. Rai R.S., Regan L., Clifford K., et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995, 10:2001-2005.
5. Yetman D.L., Kutteh W.H. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996, 66:540-546.
6. Branch D.W., Silver R.M., Porter T.F. Obstetric antiphospholipid syndrome: current uncertainties should guide our way. Lupus 2010, 19:446-452.
7. Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408-413.
8. Laskin C.A., Spitzer K.A., Clark C.A., et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009, 36:279-287.
9. Branch D., The Obstetric Task Force Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies. Lupus 2011, 20:158-164.
10. Silver R.M. Fetal death. Obstet Gynecol 2007, 109:153-167.
11. Smith G.C.S., Crossley J.A., Aitken D.A., et al. First-trimester placentation and the risk of antepartum stillbirth. JAMA 2004, 292:2249-2254.
12. Oshiro B.T., Silver R.M., Scott J.R., et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996, 87:489-493.
13. Meis P.J., Goldenberg R.L., Mercer B.M., et al. The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol 1998, 178:562-567.
14. Clark E.A., Silver R.M., Branch D.W. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?. Curr Rheumatol Rep 2007, 9:219-225.
15. do Prado A.D., Piovesan D.M., Staub H.L., et al. Association of anticardiolipin antibodies with preeclampsia. A systematic review and meta-analysis. Obstet Gynecol 2010, 116:1433-1443.
16. De Wolf F., Carreras L.O., Moerman P., et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982, 142:829-834.
17. Hanly J.G., Gladman D.D., Rose T.H., et al. Lupus pregnancy. A prospective study of placental changes. Arthritis Rheum 1988, 31:358-366.
18. Nayar R., Lage J.M. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome: a case report and review of the literature. Hum Pathol 1996, 27:201-206.
19. Peaceman A.M., Rehnberg K.A. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production. Am J Obstet Gynecol 1993, 169:1403-1406.
20. Van Horn J.T., Craven C., Ward K., et al. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004, 25:642-648.
21. Rand J.H. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002, 11:29-37.
22. Rand J.H., Wu X.X., Guller S., et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994, 171:1566-1572.
23. Rand J.H., Wu X.X., Quinn A.S., et al. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010, 19:460-469.
24. Out H.J., Kooijman C.D., Bruinse H.W., et al. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991, 41:179-186.
25. Di Simone N., Luigi M.P., Marco D., et al. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann N Y Acad Sci 2007, 1108:505-514.
26. Sebire N.J., Fox H., Backos M., et al. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 2002, 17:1067-1071.
27. Di Simone N., Meroni P.L., de Papa N., et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000, 43:140-150.
28. Katsuragawa H., Kanzaki H., Inoue T., et al. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod 1997, 56:50-58.
29. Adler R.R., Ng A.K., Rote N.S. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol Reprod 1995, 53:905-910.
30. Rote N.S., Vogt E., DeVere G., et al. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol 1998, 39:125-136.
31. Di Simone N., Marana R., Castellani R., et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum 2010, 62:1504-1512.
32. Ornoy A., Yacobi S., Matalon S.T., et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus 2003, 12:573-578.
33. Matalon S.T., Shoenfeld Y., Blank M., et al. Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome. Am J Reprod Immunol 2004, 51:144-151.
34. Borghi M.O., Raschi E., Scurati S., et al. Effects of a toll-like receptor antagonist and anti-annexin A2 antibodies on binding and activation of decidual cells by anti-β2glycoprotein I antibodies. Clin Exp Rheumatol 2007, 2:35.
35. Francis J., Rai R., Sebire N.J., et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006, 12:435-442.
36. Di Simone N., Di Nicuolo F., D'Ippolito S., et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010, 83:212-219.
37. Holers V.M., Girardi G., Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211-220.
38. Martinez de la Torre Y., Buracchi C., Borroni E.M., et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 2007, 104:2319-2324.
39. Quigg R.J., Kozono Y., Berthiaume D., et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998, 160:4553-4560.
40. Girardi G., Berman J., Redecha P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003, 112:1644-1654.
41. Redecha P., Tilley R., Tencati M., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007, 110:2423-2431.
42. Girardi G., Yarilin D., Thurman J.M., et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006, 203:2165-2175.
43. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
44. Galli M., Luciani D., Bertolini G., et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832.
45. Shamonki J.M., Salmon J.E., Hyjek E., et al. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007, 196:167.e1-167.e5.
46. Cavazzana I., Manuela N., Irene C., et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?. J Autoimmun 2007, 28:160-164.
47. Salmon J.E., Girardi G. Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation. Trans Am Clin Climatol Assoc 2007, 118:99-114.
48. Brandt J.T., Triplett D.A., Alving B., et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995, 74:1185-1190.
49. Pengo V., Tripodi A., Reber G., et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009, 10:1737-1740.
50. Pierangeli S.S., Harris E.N. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc 2008, 3:840-848.
51. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
52. Pengo V., Ruffatti A., Legnani C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010, 8:237-242.
53. Harris E.N., Gharavi A.E., Patel S., et al. Evaluation of the anticardiolipin antibody test: report of an international workshop held April 4 1986. Clin Exp Immunol 1987, 68:215-222.
54. Harris E.N. The Second International Anticardiolipin Standardization Workshop: the Kingston Anticardiolipin Antibody Study (KAPS) group. Am J Clin Pathol 1990, 101:616-624.
55. Harris E.N., Pierangeli S., Birch D. Anticardiolipin wet workshop report: Vth international symposium on antiphospholipid antibodies. Am J Clin Pathol 1994, 101:616-624.
56. Pierangeli S.S., Stewart M., Silva L.K., et al. Report of an anticardiolipin workshop during the VIIth International Symposium on antiphospholipid antibodies. J Rheumatol 1998, 25:156-162.
57. Reber G., Arvieux J., Comby D., et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemost 1995, 73:444-452.
58. Wong R.C.W., Wilson R.J., Pollock W., et al. Anticardiolipin antibody testing and reporting practices among laboratories participating in a large external quality assurance program. Pathology 2004, 36:174-181.
59. Tincani A., Allegri F., Sanmarco M., et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations-a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001, 86:575-583.
60. Bertolaccini M.L., Amengual O., Atsumi O., et al. " Non-criteria" aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011, 20:191-205.
61. Laroche P., Berard M., Rouquette A.M., et al. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol 1996, 106:549-554.
62. Bertolaccini M.L., Roch B., Amengual O., et al. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol 1998, 37:1229-1232.
63. Fialova L., Mikulikova L., Matous-Malbohan I., et al. Prevalence of various antiphospholipid antibodies in pregnant women. Physiol Res 2000, 49:299-305.
64. Amoroso A., Mitterhofer A.P., Del Porto F., et al. Antibodies to anionic phospholipids and anti-β2GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003, 64:265-273.
65. Tebo A.E., Jaskowski T.D., Phansalkar A.R., et al. Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol 2008, 129:870-875.
66. Tebo A.E., Jaskowski T.D., Hill H.R., et al. Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. Clin Exp Immunol 2008, 154:332-338.
67. Matzner W., Chong P., Xu G., et al. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions. J Reprod Med 1994, 39:27-30.
68. Gilman-Sachs A., Lubinski J., Beer A.E., et al. Patterns of anti-phospholipid antibody specificities. J Clin Lab Immunol 1991, 35:83-88.
69. Campbell A.L., Pierangeli S.S., Wellhausen S., et al. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995, 73:529-534.
70. Merkel P.A., Chang Y.C., Pierangeli S.S., et al. Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with a variety of connective tissue diseases. J Rheumatol 1999, 26:591-596.
71. Harris E.N., Pierangeli S.S. A more specific ELISA assay for the detection of antiphospholipid antibodies. Clin Immunol Newslett 1995, 15:26-28.
72. Day H.M., Thiagarajan P., Ahn C., et al. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998, 25:667-674.
73. Franklin R.D., Kutteh W.H. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 2003, 101:455-462.
74. Franklin R.D., Kutteh W.H. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 2002, 17:2981-2985.
75. Branch D.W., Silver R., Pierangeli S., et al. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997, 89:549-555.
76. Cucurull E., Gharavi A.E., Diri E., et al. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999, 318:55-60.
77. Kutteh W.H., Corey A., Jaslow C.R. Antiphospholipid antibodies and recurrent pregnancy loss: prevalence of anticardiolipin antibodies, the lupus anticoagulant, and antiphosphatidyl serine antibodies. Lupus 2010, 19:C156. [abstract].
78. Bertolaccini M.L., Atsumi T., Khamashta M.A., et al. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998, 25:1104-1108.
79. Donohoe S., Mackie I.J., Isenberg D., et al. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001, 113:544-549.
80. Vaarala O., Puurunen M., Manttari M., et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996, 75:456-459.
81. Horbach D.A., van Oort E., Donders R.C., et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996, 76:916-924.
82. Galli M., Beretta G., Daldossi M., et al. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997, 77:486-491.
83. Forastiero R.R., Martinuzzo M.E., Cerrato G.S., et al. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997, 78:1008-1014.
84. Pierangeli S.S., Liu X.W., Barker J.H., et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995, 74(5):1361-1367.
85. Lopez L.R., Santos M.E., Espinoza L.R., et al. Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion. Am J Clin Pathol 1992, 98:449-454.
86. Molina J.F., Gutierrez-Urena S., Molina J., et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997, 24:291-296.
87. Wong K.L., Liu H.W., Ho K., et al. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol 1991, 18:1187-1192.
88. Kalunian K.C., Peter J.B., Middlekauff H.R., et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988, 85:602-608.
89. Selva-O'Callaghan A., Ordi-Ros J., Monegal-Ferran F., et al. IgA anticardiolipin antibodies-relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998, 79:282-285.
90. Alarcon-Segovia D., Delezé M., Oria C.V., et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989, 68:353-365.
91. Spadaro A., Riccieri V., Terracina S., et al. Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus 2000, 9:56-60.
92. Diri E., Cucurull E., Gharavi A.E., et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 1999, 8:263-268.
93. Bertolaccini M.L., Atsumi T., Escudero-Contreras A., et al. The value of IgA antiphospholipid testing for the diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001, 28:2637-2643.
94. Danowski A., Kickler T.S., Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 2006, 33:1775-1779.
95. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010, 19:419-423.
96. Yamada H., Tsutsumi A., Ichikawa K., et al. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum 1999, 42:2727-2728.
97. Lee R.M., Branch D.W., Silver R.M. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001, 185:748-753.
98. Lakos G., Kiss E., Regeczy N., et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (β2GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999, 117:574-579.
99. Lee R.M., Brown M.A., Branch D.W., et al. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol 2003, 102:294-300.
100. Kumar S., Papalardo E., Sunkureddi P., et al. Isolated elevation of IgA anti-beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus 2009, 18:1011-1014.
101. Mak A., Cheung M., Cheak A., et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live birth in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 2010, 49:281-288.
102. Ziakas P., Pavlov M., Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and metaanalysis. Obstet Gynecol 2010, 115:1256-1262.
103. Fogerty A.E., Connors J.M. Management of inherited thrombophilia in pregnancy. Curr Opin Endocrinol Diabetes Obes 2009, 16:464-469.
104. Benedetto C., Marozio L., Tavella A.M., et al. Coagulation disorders in pregnancy: acquired and inherited thrombophilias. Ann N Y Acad Sci 2010, 1205:106-117.
105. Werner E.F., Lockwood C.J. Thrombophilias and stillbirth. Clin Obstet Gynecol 2010, 53:617-627.
106. Robertson L., Wu O., Langhorne P., et al. Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2005, 132:171-196.
107. Dizon-Townson D., Miller C., Sibai B., et al. The relationship of the Factor V Leiden mutation in pregnancy outcomes for mother and fetus. Obstet Gynecol 2005, 106:517-524.
108. Rodger M.A., Betancourt M.T., Clark P., et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010, 7(6):e1000292.
109. Clark P., Walker I.D., Langhorne P., et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010, 115:4162.
110. Kaandorp S.P., Goddijn M., van der Post J.A., et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010, 362:1586-1596.